[Hepatitis delta: Clinical aspects and therapeutic perspectives]

Abstract : HDV prevalence must not be disregarded, as the virus is associated with a higher severity of hepatic disease. All HBV carriers should be tested for HDV as well, at least once during the disease history, and in case of worsening of a chronic HBV hepatitis. Diagnosis should rely on anti-HDV antibody testing, and confirmed by HDV RNA detection and quantification by RT-qPCR. The only treatment available is pegylated alpha interferon. Optimal duration of treatment has not yet been proven, and relapses are common. Disease follow-up should be carried on even when SVR is obtained, in order to track late viral relapses, and fibrosis complications (such as HCC screening)
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-lyon1.archives-ouvertes.fr/hal-01795725
Contributor : Lauriane Pillet <>
Submitted on : Friday, May 18, 2018 - 4:39:13 PM
Last modification on : Thursday, June 7, 2018 - 2:56:03 PM

Identifiers

Collections

Citation

Dulce Alfaiate, Clothilde Miaglia, Fabien Zoulim. [Hepatitis delta: Clinical aspects and therapeutic perspectives]. La Presse Médicale, Elsevier Masson, 2017, 46, pp.271-281. ⟨10.1016/j.lpm.2016.10.013⟩. ⟨hal-01795725⟩

Share

Metrics

Record views

36